New Advances in the Study of CMTM6, a Focus on Its Novel Non-Canonical Cellular Locations, and Functions beyond Its Role as a PD-L1 Stabilizer
Authors:
- Pedro Ivan Urciaga-GutierrezPUPedro Ivan Urciaga-Gutierrez
- Ramon Antonio Franco-TopeteRFRamon Antonio Franco-Topete
- Blanca Estela Bastidas-RamirezBBBlanca Estela Bastidas-Ramirez
- Fabiola Solorzano-IbarraFSFabiola Solorzano-Ibarra
- Jose Manuel Rojas-DiazJRJose Manuel Rojas-Diaz
- Nadia Tatiana Garcia-BarrientosNGNadia Tatiana Garcia-Barrientos
- Ksenia Klimov-KravtchenkoKKKsenia Klimov-Kravtchenko
- Martha Cecilia Tellez-BañuelosMTMartha Cecilia Tellez-Bañuelos
- Pablo Cesar Ortiz-LazarenoPOPablo Cesar Ortiz-Lazareno
- Oscar Peralta-ZaragozaOPOscar Peralta-Zaragoza
- Angelica Meneses-AcostaAngelica Meneses-Acosta
- Alan Guillermo Alejandre-GonzalezAAAlan Guillermo Alejandre-Gonzalez
Open Access
Abstract
CMTM6 is a membrane protein that acts as a regulator of PD-L1, maintaining its expression on the cell surface, and can prevent its lysosome-mediated degradation. It is unknown if CMTM6 is present in the plasma of patients with cervical cancer, and if it has non-canonical subcellular localizations in cell lines derived from cervical cancer. Our objective was to determine whether CMTM6 is found in plasma derived from cervical cancer patients and its subcellular localization in cell lines. Patient plasma was separated into exosome-enriched, exosome-free, and total plasma fractions. The levels of CMTM6 in each fraction were determined using ELISA and Western blot. Finally, for the cellular model, HeLa, SiHa, CaSki, and HaCaT were used; the subcellular locations of CMTM6 were determined using immunofluorescence and flow cytometry. Soluble CMTM6 was found to be elevated in plasma from patients with cervical cancer, with a nearly three-fold increase in patients (966.27 pg/mL in patients vs. 363.54 pg/mL in controls). CMTM6 was preferentially, but not exclusively, found in the exosome-enriched plasma fraction, and was positively correlated with exosomal PD-L1; CMTM6 was identified in the membrane, intracellular compartments, and culture supernatant of the cell lines. These results highlight that CMTM6, in its various presentations, may play an important role in the biology of tumor cells and in immune system evasion.Keywords
Funding Information
- Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT CF-MG-20191007114743133-61531, CUCS 277752-2024)
- Universidad de Guadalajara (CONAHCYT CF-MG-20191007114743133-61531, CUCS 277752-2024)
This publication has 33 references indexed in Scilit:
- Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesisSeminars in Cancer Biology, 2022
- CMTM6 as a master regulator of PD-L1Cancer Immunology, Immunotherapy, 2022
- Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and DegradationJournal of Medicinal Chemistry, 2022
- OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathwayCancer Immunology, Immunotherapy, 2020
- Exosomal PD-L1: Roles in Tumor Progression and ImmunotherapyTrends in Cancer, 2020
- Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpressionInternational Immunopharmacology, 2020
- CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancersBiochemistry and Biophysics Reports, 2019
- CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomasEBioMedicine, 2018
- Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancersLaboratory Investigation, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014